Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier:
NCT01576666
First received: April 10, 2012
Last updated: February 18, 2016
Last verified: February 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: April 2015
  Primary Completion Date: April 2015 (Final data collection date for primary outcome measure)